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The Effectiveness of Oxandrolone in 
Promoting Linear Growth in 
Growth Hormone Deficient Children 
Charles B. Wol f , M D , * Raymond C. Mel l inger, M D , * * Lewis B. Mor row, MD,* 
and M. Saeed-uz Zafar, M D * * * * 
This two-year study consisted of a compari-
son of oxandrolone and growth hormone for 
the treatment of five children with doc-
umented growth hormone deficiency. Previ-
ously, androgens have been reported to be 
relatively ineffective in accelerating linear 
growth In growth hormone deficient children. 
Oxandrolone was administered for one year. 
Growth hormone was added in the second six 
months and then was given as a single agent in 
the third six months. Growth accelerated 
markedly in all patients. Only one child 
showed more rapid growth with the addition of 
growth hormone while two children actually 
grew more rapidly under the Influence of ox-
androlone alone. Growth was poor and di-
minished when growth hormone was given as 
a single agent in the third six-month period for 
three children but improved when oxan-
drolone was re-instituted in a fourth six-month 
treatment period. These results suggest that 
oxandrolone may prove to be an effective and 
safe substitute for growth hormone in the 
management of selected cases of 
hypopituitarism. 
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O X A N D R O L O N E has been employed 
increasingly in thet reatment of shortness 
of stature of d i f fer ing etiology because of 
its high anabolic potency and low viri l iz-
ing p r o p e r t i e s . S t r u c t u r a l l y the an-
drogen is 17 alpha-methyl-2-oxa-5 alpha 
androstan-17 beta-ol-3-one. It has been 
suggested that androgens enhance the 
secretion of growth hormone and that 
this may be responsible for the pubertal 
growth s p u r t . A l s o , there is evidence 
that an androgen is inef fect ive as an 
anabolic agent in hypophysectomized 
animals. ' " Androgens previously have 
been found to be less anabolic in growth 
hormone deficient chi ldren than in chil-
dren w i th shortness of stature due to 
other causes . " " " The nitrogen storing ef-
fect of androgen is not dependent upon 
growth hormone, however, and does not 
involve exclusively the same metabolic 
mechanism inasmuch as the two hor-
mones have been shown to manifest 
separate protein anabolic effects and to 
These data were presented in part at the XIII 
International Congress of Pediatrics, Vienna, 
1971. 
Address reprint requests to Dr. Wolf at Henry 
Ford Hospital, 2799 West Grand Boulevard, 
Detroit, Ml 48202 
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synergize when given to rats.'" Further-
more , testosterone is capable of aug-
menting nitrogen storage in acromegalic 
subjects w h o are presumably already 
max ima l l y s t i m u l a t e d by g r o w t h 
h o r m o n e . A study was therefore de-
signed in wh ich oxandro lone was ad-
m i n i s t e r e d to f ive c h i l d r e n w i t h 
d o c u m e n t e d g r o w t h h o r m o n e d e f i -
ciency, and compared to growth hor-
mone as an agent for induc ing linear 
growth in the same chi ldren. 
Materials and Methods 
Subjects: 
f o r study five chi ldren were chosen 
ranging in age f rom 10 and ''/12 years to 12 
and */i2 years. All were dwarfed and had 
physical characteristics compatible wi th 
hypop i tu i ta r i sm. All had g rowth hor-
mone def ic iency p roved by rad io im-
munoassay after arginine and insulin in-
f us i on . They had no o ther d isorders 
which might cause shortness of stature. 
All had retardation of osseous maturation 
(delayed bone age). None had clinical 
h y p o g l y c e m i a . O n e pa t i en t had a 
craniopharyngioma (postoperative) wi th 
residual diabetes insipidus and had not 
manifested a "ca tch-up" spurt of growth 
fo l lowing surgery. 
5fud/es; 
Growth hormone deficiency was reaf-
f i rmed after arginine and insulin stimula-
t ion immedia te ly p r io r to t rea tment . 
Growth hormone release was then reas-
sessed after nine days of oxandrolone 
treatment and after six months of oxan-
d ro lone t rea tment . Oxandro lone was 
given (.1 mg per ki logram body weight 
per day) for six months and then growth 
hormone was added to the regimen for 
six mon ths ( two uni ts th ree t imes a 
week) . The th i rd six-month treatment in-
terval consisted of human growth hor-
mone wi thout concomitant oxandrolone 
and the four th treatment period of six 
months consisted of the administration 
of oxandrolone alone. The total durat ion 
of treatment was two years. SGOT, PBI, 
CBC and growth hormone antibody were 
determined every two months and bone 
age was assessed every six months. 
Results 
Growth accelerated markedly in all 
cases ranging f r om 3% inches to bVi 
inches wi th one year and 6Vs inches to 9^* 
inches wi th two years of treatment (Table 
1). The addit ion of HGH after six months 
of oxandrolone led to more rapid growth 
in only one ch i ld . Two chi ldren actually 
grew more rapidly under the inf luence of 
oxandrolone alone. In two , growth was 
equal dur ing both six-month treatment 
per iods. Reassessment of growth hor-
mone responsiveness after oxandrolone 
admin is t ra t ion showed no signif icant 
augmen ta t i on or increase in g r o w t h 
Figure 1 
Graph showing growth increments for the five 
children for the two-year treatment period. 
The various treatment regimens are indicated. 
Each lasted six months. Fleight is in centime-
ters. 
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T A B L E I 
CL IN ICAL DETAILS AND GROWTH DATA FOR THE 5 CHILDREN FOR 2 Y E A R S 
6 Months 
Before 6 Months Oxandrolone 6 Months 6 Months 
Patients Treatment Oxandrolone Growth Hormone Growth Hormone Oxandrolone 
RR (M) 
10 4/12 yrs. 
N thyroid 
i ACTH 
SW (M) 
11 8/12 yrs. 
Craniopharyngioma 
Diabetes insipidus 
i thyroid 
LK(F) 
12 6/12 yrs. 
N thyroid 
N ACTH 
Familial 
CT (M) 
12 6/12 yrs. 
N thyroid 
N ACTH 
ST (M) 
11 3/12 yrs. 
N thyroid 
i ACTH 
HT 
HTt 
BA 
HT 
HTt 
BA 
HT 
HT-
BA 
HT 
HT' 
BA 
HT 
HT-
BA 
45 
4 
46y4 
7 
44'/4 
8 ' ! 
51 
5 
4 7 U 
4V2 
48V2 
2V4 
7V2 
3'... 
10'/2 
53'.-. 
2'-4 
8'; 
49% 
2Ve 
6''2 
491/2 
21/4 
41/2 
501/2 
2 
8 
31/4 
1 1 ' r 
543/4 
11/2 
9'-': 
521/4 
2% 
7 
501/8 
5'7 
51 
1/2 
10 
531/4 
2'/2 
12 • 
561/4 
11/2 
10 • 
52 
17/a 
6 
b2' 
1'2 
10'j 
571/e 
1 % 
12 
54 
1 
9 
BA - bone age 
HT - height in inches 
HTt - height increment for 6 months 
•* - gonadotropins appeared 
T A B L E II 
P E A K R E S P O N S E S O F P L A S M A 
GROWTH HORMONE TO A R G I N I N E 
AND INSULIN STIMULATION* 
Before After 9 Days After 6 Months 
Patients Treatment Oxandrolone Oxandrolone 
R.R. A 3.3 A 2.3 
1 5.6 1 1.7 
S.W. A 1,3 A 1.3 A 1.3 
1 1.6 1 1.7 1 1.0 
L.K. A 1.2 A 1.0 
1 1.1 1 1.0 
C.T. A 4.1 A 5.3 A 4.0 
1 2.6 1 2.9 1 1.7 
S.T. A 6.3 A 6.7 A 9.0 
1 4.3 1 2.9 1 27 
A - Arginine 
I - Insulin 
Values expressed are for nanograms/l ml 
(normal> 10 ng/l ml) 
hormone levels as an explanation for the 
linear growth that occurred (Table 11). 
In the th i rd six-month treatment per iod 
growth hormone was given wi thout con-
current oxandrolone. Growth , although 
better than before any treatment, was 
poor compared to the first two regimens 
— ranging f rom Vi to IV i inches. For the 
last six months of the two-year study, ox-
androlone was again given alone wi thout 
concomitant HGH and growth ranged 
f rom % of an inch to 1 % inches. Three of 
t he pat ients again man i fes ted more 
growth than when receiving HGH alone 
and one grew equally as wel l (Figure 1). 
One patient (RR) developed transient 
m i ld l eukopen ia w h i c h p r o m p t l y re-
sponded to withdrawal of oxandrolone 
for seven days. No nausea, pr iapism, hir-
sutism, SGOT elevat ion, deepening of 
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voice or other side effects occurred due 
to oxandrolone. All the patients man-
ifested increase in v igor, muscular i ty, 
weight and appetite. In none was there 
an unacceptable increase in osseous 
maturat ion. Bone age increased in al l , but 
remained signif icant ly be low chrono-
logical age. None developed antibodies 
to human growth hormone. LK appar-
ently responded best, growing bV2 inches 
in the first year and IV i inches in the th i rd 
t rea tment pe r i od under HGH a lone . 
Then she grew only % of an inch in the 
last pe r iod . She had begun excret ing 
gonadotropins and had breast develop-
ment at that t ime. 
Discussion and Conclusion 
Published data indicate that androgens 
general ly are relat ively inef fec t ive in 
hypop i tu i ta r i sm. ' ' - " In this series oxan-
drolone was not only effective, but it re-
mained effective even after the chi ldren 
had been treated for one year wi th HGH. 
Growth occurred at a maximal rate in four 
chi ldren in the first six-month treatment 
per iod when oxandrolone was given as a 
single agent. It has been suggested that 
patients wi l l grow maximally (manifest 
"ca tch-up" growth) in response to the 
first agent administered. However, these 
patients in general responded better to 
oxandrolone than to growth hormone 
except for LK who may have exhibited 
"d imin ish ing returns" due to age (Table 
I). We have studied other GH deficient 
patients (unreported data) w h o , having 
grown wel l in response to growth hor-
mone, sustained their growth rate wi th 
oxandrolone therapy after GH supplies 
were exhausted. It therefore appears that 
the excellent growth seen in the first 
treatment period is not necessarily due to 
the fact that there had been no pr ior 
treatment. 
In view of the fact that hypopituitary 
patients in this small series grew wel l 
when oxandro lone was admin is te red 
alone, it appears to us that this anabolic 
steroid may be used as a safe substitute 
for growth hormone in the management 
of some cases of d w a r f i s m due to 
hypopitui tar ism. 
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